|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CLDN12 |
Gene summary for CLDN12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CLDN12 | Gene ID | 9069 |
| Gene name | claudin 12 | |
| Gene Alias | CLDN12 | |
| Cytomap | 7q21.13 | |
| Gene Type | protein-coding | GO ID | GO:0001894 | UniProtAcc | B2R687 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9069 | CLDN12 | LZE20T | Human | Esophagus | ESCC | 7.24e-03 | 1.47e-02 | 0.0662 |
| 9069 | CLDN12 | LZE24T | Human | Esophagus | ESCC | 8.08e-05 | 1.30e-01 | 0.0596 |
| 9069 | CLDN12 | P2T-E | Human | Esophagus | ESCC | 1.39e-11 | 1.45e-01 | 0.1177 |
| 9069 | CLDN12 | P4T-E | Human | Esophagus | ESCC | 8.00e-11 | 2.30e-01 | 0.1323 |
| 9069 | CLDN12 | P5T-E | Human | Esophagus | ESCC | 1.41e-07 | 1.73e-02 | 0.1327 |
| 9069 | CLDN12 | P8T-E | Human | Esophagus | ESCC | 1.25e-23 | 2.40e-01 | 0.0889 |
| 9069 | CLDN12 | P9T-E | Human | Esophagus | ESCC | 8.05e-12 | 1.12e-01 | 0.1131 |
| 9069 | CLDN12 | P10T-E | Human | Esophagus | ESCC | 3.97e-10 | 1.24e-01 | 0.116 |
| 9069 | CLDN12 | P11T-E | Human | Esophagus | ESCC | 4.72e-05 | 2.73e-01 | 0.1426 |
| 9069 | CLDN12 | P12T-E | Human | Esophagus | ESCC | 1.18e-09 | 2.60e-01 | 0.1122 |
| 9069 | CLDN12 | P15T-E | Human | Esophagus | ESCC | 8.84e-12 | 2.55e-01 | 0.1149 |
| 9069 | CLDN12 | P16T-E | Human | Esophagus | ESCC | 2.79e-72 | 1.30e+00 | 0.1153 |
| 9069 | CLDN12 | P19T-E | Human | Esophagus | ESCC | 4.92e-04 | 2.89e-01 | 0.1662 |
| 9069 | CLDN12 | P20T-E | Human | Esophagus | ESCC | 1.78e-10 | 1.69e-01 | 0.1124 |
| 9069 | CLDN12 | P21T-E | Human | Esophagus | ESCC | 2.40e-19 | 1.92e-01 | 0.1617 |
| 9069 | CLDN12 | P22T-E | Human | Esophagus | ESCC | 3.00e-10 | 3.28e-02 | 0.1236 |
| 9069 | CLDN12 | P23T-E | Human | Esophagus | ESCC | 1.46e-18 | 4.61e-01 | 0.108 |
| 9069 | CLDN12 | P24T-E | Human | Esophagus | ESCC | 4.25e-11 | 4.66e-02 | 0.1287 |
| 9069 | CLDN12 | P26T-E | Human | Esophagus | ESCC | 7.78e-14 | 2.06e-01 | 0.1276 |
| 9069 | CLDN12 | P27T-E | Human | Esophagus | ESCC | 1.63e-08 | 7.11e-02 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003563310 | Esophagus | ESCC | maintenance of blood-brain barrier | 24/8552 | 35/18723 | 5.25e-03 | 1.97e-02 | 24 |
| GO:003563315 | Prostate | Tumor | maintenance of blood-brain barrier | 17/3246 | 35/18723 | 2.09e-05 | 2.71e-04 | 17 |
| GO:000189416 | Prostate | Tumor | tissue homeostasis | 65/3246 | 268/18723 | 2.39e-03 | 1.35e-02 | 65 |
| GO:006024915 | Prostate | Tumor | anatomical structure homeostasis | 74/3246 | 314/18723 | 2.82e-03 | 1.54e-02 | 74 |
| GO:003563319 | Thyroid | PTC | maintenance of blood-brain barrier | 19/5968 | 35/18723 | 4.94e-03 | 2.29e-02 | 19 |
| GO:003563322 | Thyroid | ATC | maintenance of blood-brain barrier | 22/6293 | 35/18723 | 3.74e-04 | 2.28e-03 | 22 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CLDN12 | SNV | Missense_Mutation | c.584N>C | p.Trp195Ser | p.W195S | P56749 | protein_coding | tolerated(0.05) | probably_damaging(0.996) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| CLDN12 | SNV | Missense_Mutation | novel | c.25N>T | p.Ala9Ser | p.A9S | P56749 | protein_coding | tolerated(0.57) | benign(0.086) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
| CLDN12 | SNV | Missense_Mutation | c.461N>A | p.Val154Asp | p.V154D | P56749 | protein_coding | deleterious(0.03) | benign(0.031) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| CLDN12 | insertion | Frame_Shift_Ins | novel | c.290_291insTTGTG | p.Met98CysfsTer10 | p.M98Cfs*10 | P56749 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| CLDN12 | insertion | Frame_Shift_Ins | novel | c.291_292insTTAAACTCTGATTTTTATATTGTACATTTATATATGCT | p.Met98LeufsTer21 | p.M98Lfs*21 | P56749 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| CLDN12 | insertion | Nonsense_Mutation | novel | c.267_268insAAGCAGTGAGCTGGGTCACTGAATGCTAAGAAGTAGTTAA | p.Leu90LysfsTer3 | p.L90Kfs*3 | P56749 | protein_coding | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CLDN12 | SNV | Missense_Mutation | c.551N>A | p.Gly184Asp | p.G184D | P56749 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CLDN12 | SNV | Missense_Mutation | c.556N>C | p.Phe186Leu | p.F186L | P56749 | protein_coding | tolerated(0.75) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| CLDN12 | SNV | Missense_Mutation | c.586N>A | p.Tyr196Asn | p.Y196N | P56749 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-A02J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| CLDN12 | SNV | Missense_Mutation | c.248N>C | p.Leu83Pro | p.L83P | P56749 | protein_coding | deleterious(0.04) | probably_damaging(0.917) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |